ENDRA Life Sciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
ENDRA Life Sciences Stock-Based Compensation Growth & History (NDRA)
ENDRA Life Sciences's stock-based compensation was $329,409 for fiscal 2025.
View full ENDRA Life Sciences company overviewENDRA Life Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $329,409 | −$242,515 | −42.40% |
| 2024 | 2024-12-31 | $571,924 | −$424,506 | −42.60% |
| 2023 | 2023-12-31 | $996,430 | −$203,408 | −16.95% |
| 2022 | 2022-12-31 | $1.2M | −$244,734 | −16.94% |
| 2021 | 2021-12-31 | $1.4M | −$657,780 | −31.29% |
| 2020 | 2020-12-31 | $2.1M | — | — |
ENDRA Life Sciences quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $541,904 | $502,374 | +1270.87% |
| Q1 2026 | 2026-03-31 | $574,451 | $491,405 | +591.73% |
| Q4 2025 | 2025-12-31 | $62,111 | — | — |
| Q3 2025 | 2025-09-30 | $144,722 | — | — |
| Q2 2025 | 2025-06-30 | $39,530 | −$147,060 | −78.81% |
| Q1 2025 | 2025-03-31 | $83,046 | −$234,451 | −73.84% |
| Q2 2024 | 2024-06-30 | $186,590 | −$69,265 | −27.07% |
| Q1 2024 | 2024-03-31 | $317,497 | $80,218 | +33.81% |
| Q4 2023 | 2023-12-31 | $250,557 | — | — |
| Q3 2023 | 2023-09-30 | $252,739 | −$656,330 | −72.20% |
| Q2 2023 | 2023-06-30 | $255,855 | — | — |
| Q1 2023 | 2023-03-31 | $237,279 | −$51,258 | −17.76% |
| Q3 2022 | 2022-09-30 | $909,069 | $581,270 | +177.33% |
| Q1 2022 | 2022-03-31 | $288,537 | −$33,412 | −10.38% |
| Q4 2021 | 2021-12-31 | $411,737 | — | — |
| Q3 2021 | 2021-09-30 | $327,799 | — | — |
| Q2 2021 | 2021-06-30 | $383,087 | — | — |
| Q1 2021 | 2021-03-31 | $321,949 | — | — |
ENDRA Life Sciences stock-based compensation trends
Over the last five fiscal years, ENDRA Life Sciences's stock-based compensation decreased from $2.1M to $329,409, a change of −$1.8M. The latest reported quarter, Q2 2026, shows $541,904.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ENDRA Life Sciences source filings ↗